Sanofi's upgraded 2026 outlook, Dupixent growth and attractive valuation give it an edge over AbbVie, despite pipeline setbacks and vaccine sales challenges.
Sanofi's offer to rectify the potential effects of its past messages on a rival flu shot awould address concerns, the bloc's executive arm said.
SNY and REGN expand their longstanding alliance to four new antibodies targeting type II inflammation, with billions in potential payments.
| Pharmaceuticals Industry | Healthcare Sector | Belén Garijo López CEO | LSE Exchange | 80105N105 CUSIP |
| FR Country | 76,493 Employees | 4 May 2026 Last Dividend | 30 Sep 2013 Last Split | - IPO Date |
Sanofi is a global leader in healthcare, deeply engaged in the journey of pushing the boundaries of medicine to improve health outcomes across the world. Founded in 1973 and headquartered in Paris, France, the company has evolved its name from Sanofi-Aventis to Sanofi in May 2011, marking a milestone in its expansive history. With a robust presence in the United States, Europe, and various international markets, Sanofi undertakes the research, development, manufacture, and marketing of therapeutic solutions through a comprehensive portfolio segmented into Pharmaceuticals, Vaccines, and Consumer Healthcare. The company's dedication to innovation is underscored by its collaborations, including a notable one with GlaxoSmithKline for a Covid-19 vaccine and a research venture with Stanford University School of Medicine focused on immunology and inflammation. Furthermore, Sanofi's partnership with Prellis Biologics, Inc., showcases its commitment to exploring new horizons in healthcare solutions.